ProfileGDS5678 / 1425269_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 73% 76% 75% 77% 74% 75% 77% 73% 74% 74% 73% 72% 73% 72% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.6561873
GSM967853U87-EV human glioblastoma xenograft - Control 25.0930176
GSM967854U87-EV human glioblastoma xenograft - Control 34.9087175
GSM967855U87-EV human glioblastoma xenograft - Control 45.3179977
GSM967856U87-EV human glioblastoma xenograft - Control 54.824374
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.8368275
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.1029577
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.7462973
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.8662374
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.9247374
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.6420573
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.5869772
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.730673
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.5937872